Biologicals in severe chronic rhinosinusitis with nasal polyps: translation to clinical practice while waiting for head-to-head studies

Autores da FMUP

• Bernardo Manuel De Sousa Pinto

  Autor

• José Luís Dias Delgado

  Autor

• Diana Margarida Gonçalves Solha Pereira Da Silva

  Autor

Participantes de fora da FMUP

• Boechat, JL

Unidades de investigação

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

• Medicina da Comunidade, Informação e Decisão em Saúde

• Patologia

• RISE-Health

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

<jats:p>Dear Editor: Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1.0-2.6% of the population (1) and results in relevant direct and indirect costs. Recently, several randomized controlled trials (RCTs) with Type 2-targeting biologicals (anti-IL4R?, anti-IL5R, anti-IL5 and anti-IgE) opened a new treatment field for patients refractory to first-line treatments (2,3).</jats:p>

Keywords

• Biological Products; Chronic Disease; Humans; Nasal Polyps; Rhinitis; Sinusitis; biological product; chronic disease; human; nose polyp; rhinitis; sinusitis